PRESSEPORTAL Presseportal Logo
All Stories
Follow
Subscribe to Bosch Healthcare Solutions GmbH

14.01.2021 – 15:07

Bosch Healthcare Solutions GmbH

SARS-CoV-2: Bosch PCR tests detect virus despite mutation
Tests also detect the mutant variants that first appeared in the UK and South Africa

Waiblingen (ots)

SARS-CoV-2 detection of the Vivalytic tests from Bosch Healthcare Solutions GmbH is not affected by the mutations that were first identified in the UK and South Africa (VOC 202012/01, B.1.1.7.; 501Y.V2, B.1.351). As the tests detect the virus by amplifying target sequences within the viral genetic material that are not influenced by the mutations present in the new strains, it is very unlikely that test performance will be impaired. This applies to the VRI multiplex test developed in collaboration with Randox Laboratories Ltd. as well as to the SARS-CoV-2 rapid test. The latter is a joint development with R-Biopharm AG which, as a singleplex rapid test, delivers a result on positive samples in less than 30 minutes and can also be used for pooling.

Contact:

Thomas Berroth
Marketing & Communication
Thomas.berroth2@de.bosch.com
+49 (0) 711 811-45 599

Original content of: Bosch Healthcare Solutions GmbH, transmitted by news aktuell